KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-κB signaling pathway
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
SB743921 is a potent inhibitor of the spindle protein kinesin and is being investigated in ongoing clinical trials for the treatment of myeloma. However, little is known about the molecular events underlying the induction of cell death in multiple myeloma (MM) by SB743921, alone or in combination treatment. Here, we report that SB743921 induces mitochondria-mediated cell death via inhibition of the NF-κB signaling pathway, but does not cause cell cycle arrest in KMS20 MM cells. SB743921-mediated inhibition of the NF-κB pathway results in reduced expression of SOD2 and Mcl-1, leading to mitochondrial dysfunction. We also found that combination treatment with SB743921 and bortezomib induces death in bortezomib-resistant KMS20 cells. Altogether, these data suggest that treatment with SB743921 alone or in combination with bortezomib offers excellent translational potential and promises to be a novel MM therapy.
Abstract
SB743921 is a potent inhibitor of the spindle protein kinesin and is being investigated in ongoing clinical trials for the treatment of myeloma. However, little is known about the molecular events underlying the induction of cell death in multiple myeloma (MM) by SB743921, alone or in combination treatment. Here, we report that SB743921 induces mitochondria-mediated cell death via inhibition of the NF-κB signaling pathway, but does not cause cell cycle arrest in KMS20 MM cells. SB743921-mediated inhibition of the NF-κB pathway results in reduced expression of SOD2 and Mcl-1, leading to mitochondrial dysfunction. We also found that combination treatment with SB743921 and bortezomib induces death in bortezomib-resistant KMS20 cells. Altogether, these data suggest that treatment with SB743921 alone or in combination with bortezomib offers excellent translational potential and promises to be a novel MM therapy.
참고문헌 (25)
- Kyle RA, "Multiple myeloma", N Engl J Med, 351, pp.1860~1873 (2004)
- San Miguel J, "A practical update on the use of bortezomib in the management of multiple myeloma", Oncologist, 11, pp.51~61 (2006)
- Chauhan D, "Targeting mitochondria to overcome conventional and bortezomib", proteasome inhibitor PS-341 resistance in multiple myeloma(MM)cells, 2004, pp.104, 2458~2466
- Ocio EM, "New drugs in multiple myeloma: mechanisms of action and phase I", II clinical findings, 2008, pp.9, 1157~1165
- Hanahan D, "The hallmarks of cancer", Cell, 100, pp.57~70 (2000)
- Vale RD, "The design plan of kinesin motors", Annu Rev Cell Dev Biol, 13, pp.745~777 (1997)
- Enos AP, "Mutation of a gene that encodes a kinesin-like protein blocks nuclear division in A. nidulans", Cell, 60, pp.1019~1027 (1990)
- Sawin KE, "Mutations in the kinesin-like protein Eg5 disrupting localization to the mitotic spindle", Proc Natl Acad Sci U S A, 92, pp.4289~4293 (1995)
- Rowinsky EK, "Neurotoxicity of Taxol", J Natl Cancer Inst Monogr, pp.107~115 (1993)
- Talapatra SK, "Mitotic kinesin Eg5 overcomes inhibition to the phase I", II clinical candidate SB743921 by an allosteric resistance mechanism, 2013, pp.56, 6317~6329
- Yin Y, "Kinesin spindle protein inhibitor SB743921 induces mitotic arrest and apoptosis and overcomes imatinib resistance of chronic myeloid leukemia cells", Leuk Lymphoma, pp.1~8 (2014)
- Tan G, "Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells", Int J Cancer, 97, pp.168~172 (2002)
- Esteve MA, "Microtubules in apoptosis induction: are they necessary?", Curr Cancer Drug Targets, 7, pp.713~729 (2007)
- Staudt LM, "Oncogenic activation of NF-kappaB", Cold Spring Harb Perspect Biol, 2, pp.a000109~ (2010)
- DiDonato JA, "NF-kappaB and the link between inflammation and cancer", Immunol Rev, 246, pp.379~400 (2012)
- Song IS, "Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells", Int J Cancer, 133, pp.1357~1368 (2013)
- 박주원, "Establishment and characterization of bortezomib-resistant U266 cell line: Constitutive activation of NF-κB-mediated cell signals and", or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis, 2014, pp.47(5), 274~279[DOI]
- Yi MJ, "Heat-shock protein 25(Hspb1) regulates manganese superoxide dismutase through activation of Nfkb (NF-kappaB)", Radiat Res, 158, pp.641~649 (2002)
- Lam LT, "Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling", Clin Cancer Res, 11, pp.28~40 (2005)
- Richardson PG, "The emerging role of novel therapies for the treatment of relapsed myeloma", J Natl Compr Canc Netw, 5, pp.149~162 (2007)
- Lonial S, "Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma", Blood, 106, pp.3777~3784 (2005)
- 송인성, "Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells", Experimental and Molecular Medicine, 45(10), pp.1~9 (2013), 생화학분자생물학회
- 공필재, "Melatonin Induces Akt Phosphorylation through Melatonin Receptor- and PI3K-Dependent Pathways in Primary Astrocytes", The Korean Journal of Physiology & Pharmacology, 12(2), pp.37~41 (2008), 대한약리학회
- Hong Xie, "Adenovirus vector-mediated FAM176A overexpression induces cell death in human H1299 non-small cell lung cancer cells", BMB Reports, 47(2), pp.104~109 (2014), 생화학분자생물학회
- Su-jian Liu, "Berberine suppresses in vitro migration of human aortic smooth muscle cells through the inhibitions of MMP-2", 9, u-PA, AP-1, and NF-κB, 2014, pp.47(7), 388~392[DOI]